Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition

BACKGROUND: ALK tyrosine kinase inhibition has become a mainstay in the clinical management of ALK fusion positive NSCLC patients. Although ALK mutations can reliably predict the likelihood of response to ALK tyrosine kinase inhibitors (TKIs) such as crizotinib, they cannot reliably predict response...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Clin Proteomics
Κύριοι συγγραφείς: Couëtoux du Tertre, Mathilde, Marques, Maud, McNamara, Suzan, Gambaro, Karen, Hoffert, Cyrla, Tremblay, Lise, Bouchard, Nicole, Diaconescu, Razvan, Blais, Normand, Couture, Christian, Pelsser, Vincent, Wang, Hangjun, McIntosh, Laura, Hindie, Valérie, Parent, Stephane, Cortes, Laetitia, Breton, Yannick-André, Pottiez, Gwenael, Croteau, Pascal, Higenell, Valerie, Izzi, Luisa, Spatz, Alan, Cohen, Victor, Batist, Gerald, Agulnik, Jason
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: BioMed Central 2020
Θέματα:
Research
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7006423/
https://ncbi.nlm.nih.gov/pubmed/32055239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12014-020-9269-6
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια